| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 79 |
| Referral date | 01 March 2009 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | Peter Littlejohns |
| Project manager: | TBC |
| Technical Lead: | Joao Vieria |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 6 August 2010 |
Nilotinib for the first line treatment of chronic myeloid leukaemia was referred to NICE as a Single Technology Appraisal (STA). NICE have recently undertaken a draft scope consultation exercise and held a scoping workshop for the proposed appraisal of dasatinib for the first line treatment of chronic myeloid leukaemia. As a result of this work, the Department of Health has now asked NICE to carry out a multiple technology appraisal of dasatinib, nilotinib and standard-dose imatinib within their licensed indications for the first-line treatment of chronic myeloid leukaemia (including part-review of TA70) as part of our 24th wave work programme. Therefore nilotinib will not be appraised through the STA process. |
For further information on our processes and methods, please see our CHTE processes and methods manual